This page contains a Flash digital edition of a book.


analysis solutions. A

The company announced that the Medicinal Chemistry Team from the University of São Paulo (USP), Brazil, has selected the Dotmatics Platform as its data management system. The team is led by Flavio da Silva Emery, a South American authority on the medicinal chemistry of natural products.

‘Medicinal chemistry is a fast- moving area. We are focused on rapidly advancing our research while following all of the correct legal requirements to conform to Brazilian and worldwide pharmaceutical

medicinal chemistry team in Brazil is to accelerate its research using Dotmatics’ data management and

standards. After exhaustive evaluation, we concluded that the Dotmatics Platform will fulfil our current and future requirements,’ said Dr da Silva Emery. ‘We are positive that we will save considerable time and money by avoiding the repetition of experiments.’

For regular news updates, please visit

Dotmatics chosen for Brazilian research initiative

Preto. The deployment of Studies Notebook will facilitate the recording of research results and ease the continuity of research projects across generations of students and researchers. The system’s main benefits include the ability to search through


Dotmatics says the platform will enable Dr da Silva Emery’s group to keep a detailed register of the natural compounds harvested from several Brazilian biomes as well as the novel compounds synthesised in Ribeirão

experiment results going back several years as well as revealing multiple data types in a single view. This data can then be used to perform complex analysis and pick leads that can be further developed into new drugs.

Karo Bio chooses Elsevier’s Reaxys products to support chemical research


lsevier has announced that Karo Bio, a developer of drugs for large medical needs, has started to use its Reaxys and Reaxys Medicinal Chemistry products. Karo Bio says it has chosen the solutions to support its chemists in their research and development objectives, ensuring that they have quick and easy access to state-of-the-art chemistry information. Reaxys, with its recent expansion of chemistry data and capabilities now encompassing content of more than 16,000 periodicals, is claimed to have the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from l

a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys. Adding this content to Karo Bio’s information sources means that chemists will have readily available access to relevant information, says Elsevier. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritise viable compounds, helping reduce the time it takes to bring innovative drugs to market.

‘Researchers in life sciences face an ever growing challenge in making confident and successful decisions in a changing landscape,’


said Juergen Swienty-Busch, head of product management for Reaxys. ‘Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals. We are excited that the Reaxys solutions will play a part in increasing the speed at which these projects to discover innovative compounds come to fruition.’ Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools that span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium Quosa and Embase.


BT and Schrödinger are working together to accelerate the process of drug discovery and development, using the BT for Life Sciences cloud platform and Schrödinger’s scientific software applications. As part of the initiative,

Schrödinger becomes a strategic member of the BT for Life Sciences partner ecosystem, helping provide research solutions to scientists on a global basis. Schrödinger’s software tools will be integrated into BT for Life Sciences as part of BT’s R&D Workbench environment. Built on the BT Cloud Compute platform and unveiled at the 10th Annual BioIT World meeting last year, BT for Life Sciences is the first cloud service designed to enable collaboration within the life sciences industry for increased productivity in discovery, research and development. One of Schrödinger’s key applications, Seurat, will soon be available on the BT Cloud Compute Platform. This application contains tools that help researchers in the discovery and optimisation of drug research and provides a means for sharing real- time analysis. Using the BT platform, Schrödinger can easily integrate data and scientific business processes – enhancing the early discovery process so that, ultimately, better compounds can be brought to the clinic faster.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32